Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23594627 | 0.95 | NPC1 (0.50) | NPC1CYP2D6KCNH2HRH3GNAI3 | |
| SCHEMBL29317702 | 0.94 | NPC1 (0.49) | NPC1CYP2D6KCNH2HRH3GNAI3 | |
| SCHEMBL12793198 | 0.90 | CYP2D6 (0.46) | NPC1CYP2D6KCNH2HRH3GNAI3 | |
| SCHEMBL20939041 | 0.85 | GNAI3 (0.55) | NPC1CYP2D6KCNH2HRH3GNAI3 | |
| SCHEMBL13964621 | 0.83 | GNAI3 (0.62) | NPC1CYP2D6KCNH2HRH3GNAI3 | |
| SCHEMBL17471167 | 0.83 | NPC1 (0.51) | NPC1CYP2D6KCNH2HRH3GNAI3 | |
| SCHEMBL25474715 | 0.82 | NPC1 (0.54) | NPC1CYP2D6KCNH2HRH3GNAI3 | |
| SCHEMBL17471168 | 0.82 | NPC1 (0.50) | NPC1CYP2D6KCNH2HRH3GNAI3 | |
| SCHEMBL24926179 | 0.82 | NPC1 (0.50) | NPC1CYP2D6KCNH2HRH3GNAI3 | |
| SCHEMBL23594493 | 0.81 | NPC1 (0.46) | NPC1CYP2D6KCNH2HRH3GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242337-B2 | Compounds useful for treating gastrointestinal tract disorders | ARDELYX, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11147884-B2 | Inhibitors of NHE-mediated antiport | ARDELYX, INC. (US) | 2021-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242337-B2 | Compounds useful for treating gastrointestinal tract disorders | SLC10A2, FABP2, SLC10A1 | NPC1 587/4885CYP2D6 1549/4885KCNH2 2225/4885 |
| US-11147884-B2 | Inhibitors of NHE-mediated antiport | SLC10A1, SLC10A2, SLC9A2 | NPC1 212/4885CYP2D6 1503/4885KCNH2 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.